MEDomics: New NextGen "Sequence Based" Diagnostic Test Fuels Rapid Growth

Share Article

Genetic tests for mitochondrial diseases are driving the company's rapid growth

MEDomics LLC is the first CLIA-certified laboratory focused on NextGen sequence-based molecular diagnostics. Founded by Steve Sommer, MD, PhD, in 2008, MEDomics provides Mutation-Expert-based Diagnosis and is thus the physician's trusted partner in the diagnostic revolution driven by NextGen personalized medicine.

The company’s current efforts focus on a rapidly growing and currently underserved field of medicine addressing mitochondrial diseases (OneMedPlace). According to the United Mitochondrial Disease Foundation (, a nationally recognized non-profit organization dedicated to mitochondrial diseases, a child who will develop a mitochondrial disease by age 10 is born every 30 minutes.

Approaching its 3-year anniversary, “MEDomics has had a great reception for its mitochondrial disease test in the physicians’ community” (Richard Boles, MD, Childrens Hospital Los Angeles). Clinical sales have increased about 24-fold in the last 6 months to over 2 million dollars exceeding projections, and paving the way for a profitable 2011. Over 10 million dollars in revenue is anticipated in 2011.

According to Dr. Sommer (President and Senior Molecular Geneticist of MEDomics) “The mitochondrial disease tests based on Next Generation sequencing improve the utilization of blood tests to evaluate patients suspected to have mitochondrial diseases. For the physician, use of the more sensitive and comprehensive molecular tests can i) dramatically simplify testing, ii) enhance the efficiency of genetic diagnoses, iii) often remove the need for invasive muscle biopsies, iv) enable rational therapy, and v) provide prognostic information for improved familial risk counseling.”

Back in 2009, MEDomics became the first CLIA certified diagnostic laboratory in the United States to focus on the application of NextGen technology in clinical medicine. Today, the revolutionary potential of NextGen sequencing is gaining substantial media and investor attention, including a recent cover story in FORBES magazine:

MEDomics will close its most recent round of financing in the 2nd quarter of 2011.

About Mitochondrial Disease:
Mitochondria are the “power plants” of the cell, producing 90 percent of the energy that the body needs to fun ction. Mutations in mitochondrial genes may decrease energy production and affect multiple organs. Since cells contain hundreds of mitochondrial DNA molecules, any particular tissue may contain mitochondrial DNA molecules that are all identical, or there may be a fraction that differs. When both normal and mutant molecules exist, the mitochondria are said to be “heteroplasmic”. The heteroplasmic fraction of mutations can differ substantially among tissues. The affected individuals often have multiple challenges including strokes, seizures, developmental delay, fatigue, stroke-like episodes, migraines, ataxia, hypotonia, multiple psychiatric illnesses, gastro-intestinal problems, swallowing difficulties, failure to thrive, blindness, deafness, heart and kidney problems, muscle failure, heat/cold intolerance, diabetes, lactic acidosis, immune system problems and liver disease.

About MEDomics:
MEDomics, LLC ( is a molecular diagnostic laboratory founded in 2008 by Steve S. Sommer, MD, PhD, with the mission of providing Mutation Expert-based Diagnosis (“MED”) to support the physician in delivering personalized medicine based on analysis of the patient’s genome (“omics”). MEDomics, located near Pasadena, CA is the first CLIA Certified Laboratory specializing in the clinical diagnostic application of Next Generation sequencing. The mutation experts at MEDomics provide unparalleled quality interpretation to aid the practicing physician.

Contact Information: For inquiries please contact
Craig Camp, CFO
MEDomics, LLC
426 N. San Gabriel Ave.
Azusa, CA 91702
Phone: (626) 804-3645

For more information on Mitochondrial Diseases, visit: MitoAction, The United Mitochondrial Disease Foundation, MEDomics


Share article on social media or email:

View article via:

Pdf Print

Contact Author


Email >
Visit website